Home/Products /brinzolamide-ip-1-w-v-benzalkonium-chloride-sodium-ip-0-01-v-v-eye-drop

Monopoly Rights for Brimonidine Tartrate Drops

Name: Brimonidine Tartrate 0.2% Eye Drop PCD Franchise
Brand: Optibrinz Eye Drop
Rating: 4.8 (150 reviews)

High Profit Margins from Chronic Glaucoma Segment

Brimotale Edge: Trusted Ophthalmic Solution

Secure Exclusive Territory in Ophthalmology Segment

Low Investment, Full Technical Marketing Support

Start Your High-Value Ophthalmic Business Today

Therapeutic

ENDOCRINOLOGY and Hormonal range

Gastroenterology

General and OTC medicines

Gynecology and Fertility

Hepatology

Hypertension/ Blood Pressure

Nutraceuticals, Multivitamins and Multiminerals

Sedative or Antianxiety

Stimulant

Urology

Brimonidine Tartrate 0.2% Franchise in Lucknow UP

Glaucoma PCD opportunity for Brimotale in Bhopal

Monopoly rights Brimonidine Eye Drop across Odisha

Ophthalmic pharma franchise opportunity in Chandigarh

Top PCD business for eye drops in Guwahati

Brimonidine Tartrate PCD Franchise Literature PDF

Optibrinz Eye Drop

Composition : Brinzolamide (1% w/v) Eye Drop

Dosage Form : Eye drop

Packaging Type : Dropper

Packaging : 5ml

Price : ₹0/-

Please Contact For Best Price

Brimotale Eye Drop (Brimonidine Tartrate 0.2% w/v) is a high-profit chronic care product built for our PCD Pharma Franchise partners.

This essential alpha-adrenergic agonist is widely used to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Since glaucoma requires lifelong treatment, this product guarantees stable, long-term prescription refills.

Why Brimotale is Your Key to Profit:

Stable, Long-Term Demand: As a cornerstone drug for glaucoma management, Brimotale ensures consistent, recurring revenue based on chronic patient needs, providing financial stability.
Specialty Market Margin: Positioned in the high-value ophthalmic segment, this product commands premium pricing and secures some of the highest profit margins within specialty eye care.
Doctor Loyalty: The established efficacy of Brimonidine Tartrate builds strong prescription loyalty from Ophthalmologists, securing your long-term success.
Monopoly Opportunity: We offer exclusive rights for your area—meaning zero competition in your designated specialty clinics. Partner with us for full marketing support and reliable supply to convert this high-value product into guaranteed business growth.

Contact us today to capture this high-margin ophthalmic segment!

About the Product

Brimotale Eye Drop (Brimonidine Tartrate 0.2% w/v) is a high-profit chronic care product built for our PCD Pharma Franchise partners.

Why Brimotale is Your Key to Profit:

Stable, Long-Term Demand: As a cornerstone drug for glaucoma management, Brimotale ensures consistent, recurring revenue based on chronic patient needs, providing financial stability.
Specialty Market Margin: Positioned in the high-value ophthalmic segment, this product commands premium pricing and secures some of the highest profit margins within specialty eye care.
Doctor Loyalty: The established efficacy of Brimonidine Tartrate builds strong prescription loyalty from Ophthalmologists, securing your long-term success.
Monopoly Opportunity: We offer exclusive rights for your area—meaning zero competition in your designated specialty clinics. Partner with us for full marketing support and reliable supply to convert this high-value product into guaranteed business growth.

Contact us today to capture this high-margin ophthalmic segment!

Patients may experience injection site discomfort, gastrointestinal upset (nausea, vomiting, diarrhea), rash, or mild liver enzyme elevations. Less commonly, hypersensitivity reactions and hematologic abnormalities such as eosinophilia or neutropenia may occur. Rare instances of C. difficile-associated diarrhea should be considered during prolonged use.

This formulation is used in the treatment of severe systemic infections such as urinary tract infections, lower respiratory tract infections (including pneumonia), intra-abdominal infections, skin and soft tissue infections, gynecological infections, and septicemia caused by susceptible gram-negative bacteria. It is particularly valuable in hospital-acquired infections or polymicrobial infections when used in combination with other antimicrobials.

This injection should only be used under the supervision of a qualified healthcare professional. Renal function should be monitored in long-term or high-dose treatments, and dose adjustment may be required in renal impairment. Aztreonam is not effective against gram-positive or anaerobic organisms, and should be used in combination therapy if mixed infections are suspected.

Store in a cool, dry place below 25°C, protected from direct sunlight. Keep the bottle tightly closed and out of reach of children.